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Abstract
Introduction: Post-transfusion purpura is a rare immunohematological disorder characterized by severe
thrombocytopenia following transfusion of blood components and induced by an alloantibody against a donor
platelet antigen. It occurs primarily in women sensitized by pregnancy and is most commonly caused by
anti-human platelet antigen-1a antibodies. Here, we describe what we believe to be the first documented case of
an African-American man who developed post-transfusion purpura due to an anti-human platelet antigen-5b
alloantibody after receiving multiple blood products.
Case presentation: A 68-year-old African-American man initially admitted with atrial flutter was started on
anticoagulation treatment, which was complicated by severe hematemesis. On days 4 and 5 of hospitalization, he
received six units of packed red blood cells, and on days 4, 13 and 14 he received plasma. His platelet count began
to drop on day 25 and on day 32 reached a nadir of 7 × 109/L. His platelet count increased after receiving
intravenous immune globulin. An antibody with reactivity to human platelet antigen-5b was detected by a
solid-phase enzyme-linked immunoassay. Our patient was homozygous for human platelet antigen-5a.
Conclusion: This case emphasizes the importance of including post-transfusion purpura in the differential diagnosis
for both men and women with acute onset of thrombocytopenia following transfusion of blood products. The
prompt recognition of this entity is crucial for initiation of the appropriate management.
Introduction
Post-transfusion purpura (PTP) is a rare immunohema-
tological disorder, characterized by a potentially life-
threatening thrombocytopenia induced in a transfusion
recipient by an alloantibody against a donor platelet
antigen, most commonly human platelet antigen (HPA)-
1a [1,2]. Most frequently it follows transfusion of cellular
blood components but it has also been described after
transfusions of plasma [3]. The diagnosis is confirmed
by detecting a circulating alloantibody to a common
platelet antigen, and by demonstrating that the patient’s
own platelets lack this antigen. PTP associated with
anti-HPA-5b antibody has been rarely reported [4] and
appears to have unique characteristics. Here, we describe
what we believe to be the first documented case of an
African-American man who developed PTP due to an
anti-HPA-5b alloantibody after receiving multiple blood
products.
Case presentation
A 68-year-old African-American man was initially ad-
mitted with atrial flutter and was started on anticoagula-
tion treatment, which was complicated by hematemesis
requiring transfer to our intensive care unit (ICU) on
day 4 of hospitalization. He had a past medical history
of packed red blood cell (PRBC) transfusion in 2002. On
admission, his blood count showed hemoglobin 13.6g/dL,
red blood cell count 5.14 × 1012/L, and platelets 265 × 109/L.
His prothrombin time was 17.6 seconds (normal range: 11.8
to 14.5 seconds), activated partial thromboplastin time was
30.4 seconds (normal range: 23.0 to 35.0 seconds) and inter-
national normalized ratio was 1.5. His ICU course was
further complicated by Moraxella catarrhalis pneumonia,
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for which he completed a course of imipenem, and by Clos-
tridium difficile colitis treated with oral vancomycin.
While in the ICU, our patient received six units of PRBC
and two units of plasma on day 4 of hospitalization, six
units of PRBC on day 5 and six units of plasma on day 13
and day 14. He clinically improved and was transferred to
the medical ward on day 21. His platelet count began to
drop rapidly on day 25 (Figure 1) and on day 29 his plate-
lets decreased to 51 × 109/L and he developed hematuria.
He was afebrile and had no signs of infection. On day 30,
his platelet count dropped to 31 × 109/L. His prothrombin
time and activated partial thromboplastin time were
normal. A peripheral blood smear was remarkable for
large platelets that were decreased in number. The differ-
ential diagnosis at this time included drug-related
thrombocytopenia, PTP and immune thrombocytopenic
purpura. Several medications were discontinued. However,
his platelet count continued to drop, reaching a nadir of
7 × 109/L on day 32. On that same day, our patient
received methylprednisolone 1mg/kg and one unit of
single-donor platelets. On day 33, intravenous immune
globulin (IVIg) was begun at a dose of 700mg/kg daily for
three doses. Two days after the first dose of IVIg, his
platelet count increased to 46 × 109/L without further
transfusions and the hematuria resolved. An enzyme-
linked immunosorbent assay for antibodies to platelet
surface glycoproteins demonstrated the presence of an
antibody with reactivity to HPA-5b. Prior to the admin-
istration of IVIg, an antibody with reactivity to HPA-5b
was detected by a solid-phase enzyme-linked immuno-
assay commercial kit (Gen-Probe, Inc., San Diego, CA,
USA), cleared for in vitro diagnostic use by the US Food
and Drug Administration. The absorbance (optical dens-
ity) of our patient’s sample was 0.27 (negative control:
0.13). Our patient’s platelet genotyping by polymerase
chain reaction and fluorescent hydrolysis revealed HPA-
5a/5a (Mayo Clinic Laboratories, Rochester, MN, USA).
Methylprednisolone was discontinued on day 34 of admis-
sion. On day 36, our patient was discharged without
bleeding manifestations and with a platelet count of 61 ×
109/L. Twenty-two days after discharge, his platelet count
had increased to 280 × 109/L.
Discussion
The only previously published case of PTP induced by
the anti-HPA-5b alloantibody was described in a white
multiparous woman after an elective hysterectomy [4].
To the best of our knowledge, our case represents the
first reported episode of confirmed PTP due to anti-
HPA-5b in an African-American man. The anti-HPA-5b
alloantibody developed after a total of 26 units of blood
products given for acute hemorrhage in the setting of
anticoagulation and multiple infections. Our patient’s
platelet count dropped after he recovered from his infec-
tion, at a time when he was clinically improving. The
first drop in platelet count was recorded 20 to 21 days
after transfusions of PRBC and 11 to 21 days after
plasma transfusion (Figure 1). Both PRBC and plasma
transfusions have been associated with PTP [5]. The
diagnosis of PTP in our patient was supported by sero-
logic studies demonstrating an alloantibody directed
against HPA-5b and by genotyping indicating that our
patient was homozygous for HPA-5a.
The incidence of PTP caused by anti-HPA-1a antibody
has been reported as one case per 50,000 to 100,000
units of transfused blood components, but this is prob-
ably an underestimate [6,7]. PTP caused by anti-HPA-5b
appears even rarer. This cannot be explained by the fre-
quency of HPA-5a and HPA-5b antigens in the general
population. The majority of the world’s population has
Figure 1 Time relationship between platelet counts, blood products and medication administered. U, unit(s); PRBC, packed red blood cell;
IVIg, intravenous immune globulin.
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genotype 5a/5a, with the highest frequencies of HPA-5b
in the United States found among African-Americans at
0.21, while Caucasians have HPA-5b gene frequency of
0.11 [8]. The calculated mismatch probability in the
HPA-5 system after random transfusions is higher than
in the HPA-1 system [9], and yet the vast majority of
reported cases of PTP are associated with the latter. The
apparent rarity of HPA-5b-associated PTP could be due
to multiple factors including decreased reporting, failure
to make the diagnosis or decreased antigenicity of the
HPA-5 compared to HPA-1 antigens [10]. The former
are expressed at a much lower density and are located
on a different platelet glycoprotein, which could result in
less antibody formation [3]. Interestingly, anti-HPA-5b
antibody is more frequently associated with neonatal
alloimmune thrombocytopenia [11]. This may be explained
by the different pathogenesis of neonatal alloimmune
thrombocytopenia compared with PTP, where the alloanti-
body causes destruction of not only HPA-5b-positive but
also HPA-5b-negative platelets [12].
Conclusion
Our report highlights the importance of considering
PTP in the differential diagnosis for both men and
women with acute onset of thrombocytopenia following
transfusion of blood products. Antibodies targeting anti-
gens other than HPA-1a, such as HPA-5b, can cause po-
tentially life-threatening bleeding and should be tested
for if PTP is suspected.
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